MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cca.2025.120775

Медицинская библиотека · Clinica chimica acta; international journal of clinical chemistry · 2025

Rapid identification and quantification of residual daratumumab in multiple myeloma patients by MALDI - TOF mass spectrometry.

Luo Hou-Long, Ding Huan, Chen Fan, Wang Yuxi, Zhou Lin, Ye Peng, Yu Hui, Wu Shangying, Xie Weijie, Ji Rui, Huang Jiatong, Su Zhenping, Xu Anping, Ji Ling

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The introduction of anti-CD38 monoclonal antibodies, including daratumumab, has significantly improved response rates and survival outcomes in multiple myeloma (MM). However, these therapeutic monoclonal antibodies (t-mAbs) interfere with conventional electrophoretic techniques used for detecting and quantifying endogenous monoclonal proteins (M-proteins), posing challenges for treatment response assessment.

METHODS

We systematically evaluated an enrichment-free, rapid MALDI-TOF mass spectrometry-based system (iMS-LC Assay) for its ability to differentiate daratumumab from M-proteins by analyzing serial serum samples from 38 multiple myeloma (MM) patients undergoing daratumumab treatment. Additionally, by spiking human serum with daratumumab, we established a reference m/z range and assessed the assay's analytical precision, limit of detection (LOD), and quantitative capabilities.

RESULTS

The iMS-LC Assay consistently identified daratumumab at a mean m/z of 23,384.63 (mean ± 3SD: 23,370-23,398), demonstrating high analytical precision (CV ≤ 2.8 %) and an LOD between 0.10 and 0.15 g/L. Daratumumab was detected in 90.55 % (182/201) of patient samples and distinguished from endogenous M-proteins in 94.74 % (36/38) of patients. It becomes challenging to distinguish t-mAbs from M-protein when the m/z of the M-protein is close to that of daratumumab and present at a high concentration.

CONCLUSION

The iMS-LC Assay facilitates specific, sensitive, and automated differentiation between daratumumab and M-proteins in most clinical settings, offering a practical alternative to traditional electrophoretic methods for monitoring treatment response in multiple myeloma patients undergoing anti-CD38 therapy.

Для цитирования: Luo Hou-Long, Ding Huan, Chen Fan, Wang Yuxi, Zhou Lin, Ye Peng, Yu Hui, Wu Shangying, Xie Weijie, Ji Rui, Huang Jiatong, Su Zhenping, Xu Anping, Ji Ling. Rapid identification and quantification of residual daratumumab in multiple myeloma patients by MALDI - TOF mass spectrometry.. Clinica chimica acta; international journal of clinical chemistry. 2025. DOI: 10.1016/j.cca.2025.120775.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.